<ul>
<li>MarketBeat 週報 – 11/24 - 11/28</li>
</ul>
<p>根據 MarketBeat 的股票篩選工具，禮來公司、艾伯維和 PTC Therapeutics 是今天值得關注的三隻製藥股票。製藥股票是指公開交易的公司股票，這些公司研究、開發、生產和銷售處方藥及相關療法，包括傳統藥品製造商和許多生物技術公司。投資者將其視為潛在的高回報但高風險，因為估值依賴於臨牀試驗結果、監管批准、專利保護和漫長的開發時間，導致事件驅動的波動性。這些公司在過去幾天內的製藥股票中交易量最高。</p>
<p>獲取 <strong>禮來公司</strong> 的提醒：</p>
<h2>禮來公司 (LLY)</h2>
<p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
<ul>
<li>一種萬億美金的藥丸：禮來打破了醫療保健的天花板</li>
</ul>
<p>閲讀我們關於 LLY 的最新研究報告</p>
<h2>艾伯維 (ABBV)</h2>
<p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥物。該公司提供 Humira，用於自身免疫性和腸道貝赫切特病以及膿皮病；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕性關節炎和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
<ul>
<li>一項宏偉的人工智能投資？斯坦利·德魯肯米勒的最新科技動態</li>
</ul>
<p>閲讀我們關於 ABBV 的最新研究報告</p>
<h2>PTC Therapeutics (PTCT)</h2>
<p>PTC Therapeutics, Inc. 是一家生物製藥公司，專注於發現、開發和商業化用於治療美國及國際上罕見疾病患者的藥物。該公司提供 Translarna 和 Emflaza 用於治療杜氏肌營養不良症；Upstaza 用於治療芳香族 L-氨基酸脱羧酶 (AADC) 缺乏症，這是一種中樞神經系統疾病；Tegsedi 和 Waylivra 用於治療罕見疾病；Evrysdi 用於治療成人和兒童的脊髓性肌萎縮症 (SMA)。</p>
<p>閲讀我們關於 PTCT 的最新研究報告</p>
<h2>精選文章</h2>
<ul>
<li>MarketBeat 十大股票推薦（2025 年 11 月）</li>
<li>CrowdStrike 在近期回調後準備反彈嗎？</li>
<li>SanDisk 加入 S&amp;P 500：指數效應的內部分析</li>
<li>亞馬遜進入修正區——是時候恐慌，還是加倉？</li>
<li>特斯拉被稱為 “必買” 股票——原因在這裏</li>
<li>為什麼黃金和特朗普一樣熱愛黃金</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
<p>在你考慮禮來公司之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而禮來公司並不在名單上。</p>
<p>雖然禮來公司目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

禮來

PTCT

艾伯維

<p>禮來公司、艾伯維和 PTC Therap 被 MarketBeat 的股票篩選工具列為今天值得關注的頂級製藥股票。這些公司的交易量最近最高。禮來專注於糖尿病和肥胖症治療，艾伯維專注於自身免疫和癌症療法，而 PTC Therap 則專注於罕見疾病。由於臨牀試驗和監管批准等因素，製藥股票屬於高風險、高回報的投資</p>

<ul>
<li>MarketBeat Week in Review – 11/24 - 11/28</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 11/24 - 11/28</li>
</ul>
</div><p>Eli Lilly and Company, AbbVie, and PTC Therapeutics are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription medicines and related therapies, including traditional drugmakers and many biotech firms. Investors view them as potentially high-reward but high-risk because valuations hinge on clinical trial results, regulatory approvals, patent protection, and long development timelines, leading to event-driven volatility. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p>
<div class="lb-trans"><p>根據 MarketBeat 的股票篩選工具，禮來公司、艾伯維和 PTC Therapeutics 是今天值得關注的三隻製藥股票。製藥股票是指公開交易的公司股票，這些公司研究、開發、生產和銷售處方藥及相關療法，包括傳統藥品製造商和許多生物技術公司。投資者將其視為潛在的高回報但高風險，因為估值依賴於臨牀試驗結果、監管批准、專利保護和漫長的開發時間，導致事件驅動的波動性。這些公司在過去幾天內的製藥股票中交易量最高。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>禮來公司</strong> 的提醒：</p>
</div><h2>Eli Lilly and Company (LLY)</h2>
<div class="lb-trans"><h2>禮來公司 (LLY)</h2>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>禮來公司在全球範圍內發現、開發和銷售人用藥物。該公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰島素利普羅、胰島素利普羅原料、胰島素利普羅混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用於糖尿病；Jardiance、Mounjaro 和 Trulicity 用於 2 型糖尿病；Zepbound 用於肥胖。</p>
</div><ul>
<li>A Trillion-Dollar Pill: Eli Lilly Broke the Healthcare Ceiling</li>
</ul>
<div class="lb-trans"><ul>
<li>一種萬億美金的藥丸：禮來打破了醫療保健的天花板</li>
</ul>
</div><p>Read Our Latest Research Report on LLY</p>
<div class="lb-trans"><p>閲讀我們關於 LLY 的最新研究報告</p>
</div><h2>AbbVie (ABBV)</h2>
<div class="lb-trans"><h2>艾伯維 (ABBV)</h2>
</div><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p>
<div class="lb-trans"><p>艾伯維公司在全球範圍內發現、開發、生產和銷售藥物。該公司提供 Humira，用於自身免疫性和腸道貝赫切特病以及膿皮病；Skyrizi 用於治療中度至重度斑塊型銀屑病、銀屑病性疾病和克羅恩病；Rinvoq 用於治療類風濕性關節炎和銀屑病性關節炎、強直性脊柱炎、特應性皮炎、軸性脊柱關節病、潰瘍性結腸炎和克羅恩病；Imbruvica 用於治療成人血癌；Epkinly 用於治療淋巴瘤；Elahere 用於治療癌症；Venclexta/Venclyxto 用於治療血癌。</p>
</div><ul>
<li>A Magnificent AI Bet? Stanley Druckenmiller’s Latest Tech Moves</li>
</ul>
<div class="lb-trans"><ul>
<li>一項宏偉的人工智能投資？斯坦利·德魯肯米勒的最新科技動態</li>
</ul>
</div><p>Read Our Latest Research Report on ABBV</p>
<div class="lb-trans"><p>閲讀我們關於 ABBV 的最新研究報告</p>
</div><h2>PTC Therapeutics (PTCT)</h2>
<div class="lb-trans"><h2>PTC Therapeutics (PTCT)</h2>
</div><p>PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.</p>
<div class="lb-trans"><p>PTC Therapeutics, Inc. 是一家生物製藥公司，專注於發現、開發和商業化用於治療美國及國際上罕見疾病患者的藥物。該公司提供 Translarna 和 Emflaza 用於治療杜氏肌營養不良症；Upstaza 用於治療芳香族 L-氨基酸脱羧酶 (AADC) 缺乏症，這是一種中樞神經系統疾病；Tegsedi 和 Waylivra 用於治療罕見疾病；Evrysdi 用於治療成人和兒童的脊髓性肌萎縮症 (SMA)。</p>
</div><p>Read Our Latest Research Report on PTCT</p>
<div class="lb-trans"><p>閲讀我們關於 PTCT 的最新研究報告</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>MarketBeat's Top Five Stocks to Own in November 2025</li>
<li>Is CrowdStrike Ready to Rally After Its Recent Pullback?</li>
<li>SanDisk Joins the S&amp;P 500: Inside the Index Effect Rally</li>
<li>Amazon Enters Correction Zone—Time to Panic, or to Load Up?</li>
<li>Tesla Just Got Called a “Must Own” Stock—Here’s Why</li>
<li>Why Gold Loves Trump as Much as Trump Loves Gold</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 十大股票推薦（2025 年 11 月）</li>
<li>CrowdStrike 在近期回調後準備反彈嗎？</li>
<li>SanDisk 加入 S&amp;P 500：指數效應的內部分析</li>
<li>亞馬遜進入修正區——是時候恐慌，還是加倉？</li>
<li>特斯拉被稱為 “必買” 股票——原因在這裏</li>
<li>為什麼黃金和特朗普一樣熱愛黃金</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在禮來公司嗎？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮禮來公司之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而禮來公司並不在名單上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然禮來公司目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

11 月 27 日值得關注的製藥類股票